Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

This study has been completed.
Sponsor:
Collaborators:
Valeant Pharmaceuticals International, Inc.
The University of Texas Health Science Center, Houston
Information provided by:
DuPont, Hurbert L., MD
ClinicalTrials.gov Identifier:
NCT00098384
First received: December 7, 2004
Last updated: May 8, 2006
Last verified: December 2004